Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Finranks

Компания

  • О нас

Контакты

  • [email protected]

Мы в соцсетях

  • Instagram
  • Telegram
  • LinkedIn

Все права защищены.

Условия использования
  • Главная
  • Рынки
  • Скринер
  • Новости
  • О нас
  1. Home
  3. SGMO
S

Sangamo Therapeutics, Inc. (SGMO)

NCM – Цена в реальном времени. Валюта: USD

0.32

-0.02 (-6.74%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

0.33

+0.01 (2.84%)

После закрытия: Mar 27, 2026, 7:42 PM EDT

  • Обзор
  • Новости
  • График
  • Финансы
  • Дивиденды
  • Прогноз
  • Владельцы
  • Профиль
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
19.03.2026

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026.

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
09.03.2026

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease.

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
03.02.2026

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed can serve as primary basis of approval Rolling submission of the Biologics License Application (BLA) to the FDA has been initiated under the Accelerated Approval pathway RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
03.02.2026

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
18.12.2025

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway  Isaralgagene civaparvovec continues to show favorable safety and tolerability profile Sangamo expects to complete Biological License Application (BLA) submission under accelerated approval pathway in second quarter of 2026 RICHMOND, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, has initiated a rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease.

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
02.12.2025

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain.

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
21.11.2025

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease.

Видео

No Data

There is no data to display